The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | Highlights from COMy 2024: risk stratification, role of MRD, and immunotherapies
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, highlights key topics from this year’s COMy meeting. Discussions covered new risk stratification methods, the role of measurable residual disease (MRD) negativity in clinical trials, and the potential of novel immunotherapies like CAR-Ts and bispecific antibodies. With progression-free survival (PFS) already extending to 10-12 years, Prof. Einsele is optimistic that multiple myeloma could be cured in the coming years. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: GlaxoSmithKline, Sanofi, Takeda, Amgen, Novartis, Janssen, Bristol Myers Squibb/Celgene; Consulting or advisory role: GlaxoSmithKline, Sanofi, Takeda, Amgen, Novartis, Janssen, Bristol Myers Squibb/Celgene; Travel support: GlaxoSmithKline, Sanofi, Takeda, Amgen, Novartis, Janssen, Bristol Myers Squibb/Celgene; Research Funding: GlaxoSmithKline, Sanofi, Takeda, Amgen, Novartis, Janssen, Bristol Myers Squibb/Celgene.
